2017
DECEMBER 29, 2017
GT Medical Technologies, Inc. completes its first round of seed financing, led by MedTech Venture Partners (MTVP) of San Francisco.
DECEMBER 20, 2017
GT Medical Technologies, Inc. is named as an awardee of the fall 2017 Arizona Innovation Challenge by the Arizona Commerce Authority, earning $250,000 in nondilutive growth capital.
2018
JULY 6, 2018
The US Food and Drug Administration provides notice of 510(k) clearance of GammaTile Therapy in the treatment of recurrent intracranial neoplasms.
MARCH 15, 2018
GT Medical Technologies, Inc. is selected as the winner of the MedTech Innovator Accelerator regional pitch competition in San Francisco.
MARCH 8, 2018
GT Medical Technologies, Inc. is selected to participate in MedTech Innovator Accelerator regional pitch competition in San Francisco on March 15th, 2018.
FEBRUARY 22, 2018
GT Medical Technologies, Inc. is selected for the 2018 Flinn Foundation entreprenuership program.
JANUARY 31, 2018
GT Medical Technologies, Inc. completes its final round of seed financing, totaling nearly $3 million. MTVP was joined by angel groups Arizona Technology Investors (ATI), Desert Angels, and Grand Canyon Angels in addition to several high-net-worth individuals.
JANUARY 8, 2018
GT Medical Technologies, Inc. announces the signing of a manufacturing and supply agreement with IsoRay Medical.
Read here
2019
DECEMBER 27, 2019
Menorah Medical Center performs new brain surgery in Kansas.
Watch here
DECEMBER 1, 2019
GammaTile permanent implants for recurrent brain tumors.
Watch here
NOVEMBER 10, 2019
What's happening in health: Liz Bonis is joined by a team to talk about brain tumor surgery.
Watch here
OCTOBER 21, 2019
Battling brain tumors with time-released radiation.
Watch here
OCTOBER 11, 2019
Fighting tumors with brain implants. El Camino doctors turn to radiation "tiles" in the fight against recurring brain tumors.
Read here
OCTOBER 1, 2019
El Camino health first on west coast to offer new targeted therapy for recurrent brain tumors.
Read here
SEPTEMBER 18, 2019
Arizona: The new frontier in technology and health care.
Read here
AUGUST 26, 2019
GT Medical Technologies, Inc. to be honored with an AZBio Fast Lane award.
Read here
AUGUST 20, 2019
Mayfield Brain and Spine neurosurgeon using new radiation therapy in Ohio.
View video
AUGUST 15, 2019
GT Medical Technologies announces completion of first case in Arizona using GammaTile Therapy.
Read here
AUGUST 14, 2019
New therapy to slow down brain tumors forever changes Arizona woman's life.
View video
JUNE 17, 2019
GT Medical Technologies announces the presentation of data demonstrating the safety profile of GammaTile Therapy for various brain tumors.
Read here
JUNE 11, 2019
GT Medical Technologies is a Tempe-based company that has created a new way to target brain tumors, like the type that took the late Senator John McCain’s life. Watch the interview with Dr. David Brachman, co-founder and Chief Technology Officer of GT Medical Technologies, to learn more.
View video
APRIL 15, 2019
Surgically targeted radiation therapy: A prospective trial in 79 recurrent, previously irradiated intracranial neoplasms. A presentation at the 2019 American Association of Neurological Surgeons annual scientific meeting.
Read here
APRIL 11, 2019
GT Medical Technologies co-founder to receive prestigious Rosenblum-Mahaley Clinical Research Award at 2019 American Association of Neurological Surgeons annual scientific meeting.
Read here
APRIL 8, 2019
Tempe-based medical tech startup improving recovery for brain tumor patients.
Read her
FEBRUARY 14, 2019
Doctors at the University of Minnesota are the first in the country to use a breakthrough brain cancer treatment.
Read here
FEBRUARY 14, 2019
University of Minnesota is the first in the U.S. to offer GammaTile Therapy, a new targeted therapy for recurrent brain tumors.
Read here
JANUARY 31, 2019
GT Medical Technologies, Inc. announces $10 million financing to support launch of targeted therapy for patients with recurrent brain tumors.
Read here
JANUARY 3, 2019
GT announces clinical trial results and accompanying publication in the Journal of Neurosurgery (JNS).
Read here
